[{"id":"382c9498-ae64-48ce-a05f-dcf78ea1d165","acronym":"","url":"https://clinicaltrials.gov/study/NCT03997968","created_at":"2021-08-12T18:53:32.634Z","updated_at":"2024-07-02T16:35:42.822Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","source_id_and_acronym":"NCT03997968","lead_sponsor":"Cyteir Therapeutics, Inc.","biomarkers":" ER • PGR • MYC • BCL2","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative","tags":["ER • PGR • MYC • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER negative • ER positive + PGR positive • PGR positive • MYC translocation • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • capecitabine • bendamustine • CYT-0851"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 10/09/2019","start_date":" 10/09/2019","primary_txt":" Primary completion: 07/30/2024","primary_completion_date":" 07/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-07-17"}]